Disease-modifying therapies in amyotrophic lateral sclerosis
Authors:
- 1 May 2020
- journal article
- review article
- Published by Elsevier in Neuropharmacology
- Vol. 167, 107986
Abstract
No abstract availableKeywords
Funding Information
- Italian Ministry of Health (RF-2016-02362405)
- Italian Ministry of Education, University and Research (2017SNW5MB)
- Joint Programme - Neurodegenerative Disease Research
- Italian Ministry of Education, University and Research
- Italian Ministry of Education, University and Research
This publication has 251 references indexed in Scilit:
- Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2013
- Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survivalEMBO Molecular Medicine, 2012
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTDNeuron, 2011
- The MSC: An Injury DrugstoreCell Stem Cell, 2011
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Autophagy: links with the proteasomeCurrent Opinion in Cell Biology, 2010
- Global Analysis of TDP-43 Interacting Proteins Reveals Strong Association with RNA Splicing and Translation MachineryJournal of Proteome Research, 2009
- Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to functional motoneuronsJournal of Tissue Engineering and Regenerative Medicine, 2009
- Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosisAnnals of Neurology, 2008